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Abstract 
Aims: Diffuse intrinsic pontine glioma (DIPG) is a childhood brainstem tumor with a median overall survival of 
eleven months. Lack of chemotherapy efficacy may be related to an intact blood-brain barrier (BBB). In this study 
we aim to investigate the neurovascular unit (NVU) in DIPG patients.  
Methods: DIPG biopsy (n = 4) and autopsy samples (n = 6) and age-matched healthy pons samples (n = 20) were 
immunohistochemically investigated for plasma protein extravasation, and the expression of tight junction pro-
teins claudin-5 and zonula occludens-1 (ZO-1), basement membrane component laminin, pericyte marker 
PDGFR-β, and efflux transporters P-gp and BCRP. The mean vascular density and diameter were also assessed. 
Results: DIPGs show a heterogeneity in cell morphology and evidence of BBB leakage. Both in tumor biopsy and 
autopsy samples, expression of claudin-5, ZO-1, laminin, PDGFR-β and P-gp was reduced compared to healthy 
pontine tissues. In DIPG autopsy samples, vascular density was lower compared to healthy pons. The density of 
small vessels (<10 µm) was significantly lower (P<0.001), whereas the density of large vessels (≥10 µm) did not 
differ between groups (P = 0.404). The median vascular diameter was not significantly different: 6.21 µm in DIPG 
autopsy samples (range 2.25-94.85 µm), and 6.26 µm in controls (range 1.17-264.77 µm). 
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Conclusion: Our study demonstrates evidence of structural changes in the NVU in DIPG patients, both in biopsy 
and autopsy samples, as well as a reduced vascular density in end-stage disease. Adding such a biological per-
spective may help to better direct future treatment choices for DIPG patients. 
 
Keywords: Diffuse intrinsic pontine glioma (DIPG), Neurovascular unit (NVU), Blood-brain barrier (BBB), Tight junctions, Brainstem, 
Pons 
Introduction 
Diffuse intrinsic pontine gliomas (DIPGs) are 
rare and aggressive childhood malignancies of the 
brainstem. These tumors are characterized by a dif-
fuse growth pattern closely interwoven within white 
matter tracts and grey matter structures, and an in-
trinsic nature, uttered by hypertrophy of the brain-
stem often encasing the basilar artery 1,2. With a me-
dian overall survival of eleven months, and a two-
year survival rate of 10%, DIPGs are the leading 
cause of brain tumor-related deaths in children 3-7. 
In the recent World Health Organization (WHO) clas-
sification of tumors of the central nervous system 
(CNS), DIPGs were reclassified as H3K27M mutated 
Diffuse Midline Gliomas (DMG H3K27M) 8. 
Though much research has been dedicated to 
DIPG, its poor outcome has remained unchanged for 
the past 40 years 9. To date, radiotherapy remains 
the only (temporarily) effective, albeit palliative 
treatment, and no chemotherapy regimens prolong-
ing survival have been identified yet. Since in vitro 
and in vivo drug testing on patient-derived tumor 
cells has shown sensitivity to conventional cytotoxic 
agents and novel drugs, the lack of efficacy in pa-
tients is hypothesized to be related to ineffective 
drug delivery due to an intact blood-brain barrier 
(BBB) 10-12. 
The BBB is formed by endothelial cells inter-
connected and sealed by tight junctions. The ablu-
minal surface of the endothelium is covered by a 
basement membrane in which pericytes are embed-
ded. Pericytes control the cerebral blood flow by 
regulating capillary diameter and vessel stability. 
The basement membrane is enclosed by astrocyte 
end-feet, also important for brain homeostasis. To-
gether, pericytes and astrocyte end-feet induce and 
maintain the integrity of the BBB 13,14. The BBB regu-
lates transport of essential nutrients to the brain 
through active transport mechanisms, such as glu-
cose transporters of the GLUT-family. The efflux of 
waste products and exogenous compounds is medi-
ated through efflux transporters of the ATP-binding 
cassette family (e.g., P-gp, BCRP, MRP-1) 14,15. Addi-
tionally, the paracellular barrier capacities of the 
tight junctions limit transport of circulating mono-
amines and drugs across the BBB 14-16. The intimate 
contact and interaction of the BBB complex, formed 
by endothelial cells, tight junctions, pericytes and as-
trocyte end-feet, with neurons and perivascular mi-
croglia form a dynamic functional unit, called the 
neurovascular unit (NVU) 13,14,16. 
Some studies report different expression of 
tight junction proteins throughout the brain, sugges-
tive of regional heterogeneity in BBB permeability 
17,18. However, little research has been done on the 
BBB and NVU in the brainstem and particularly in the 
pons. Yet, better insight into the BBB and the NVU 
at these sites is needed to develop new treatment 
strategies for pediatric brainstem tumors. This espe-
cially holds true for DIPG, where the BBB is thought 
to be a major contributor to therapeutic inefficacy. 
In this study, we aim at determining and comparing 
the histological and immunohistochemical charac-
teristics of the NVU of the pons in children with DIPG 
and age-matched controls. 
Patients and Methods 
Patients and Samples 
DIPG pre-treatment biopsy samples (n = 4) 
were obtained from the Biobank of the Princess 
Máxima Center for Pediatric Oncology, Utrecht, the 
Netherlands, and processed as formalin-fixed paraf-
fin-embedded tissue. End-stage disease DIPG au-
topsy samples (n = 6) were obtained from the ‘VUmc 
Brain autopsy in children with DIPG’ study 19. This 
study was approved by the institutional review 
board of Amsterdam UMC, location VUmc (METc 
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Figure 1: Characteristics of diffuse intrinsic pontine glioma (DIPG). A: T2-weighted MRI-image of a DIPG patient showing an expanded 
tumor at the basis of the pons. The arrow indicates the biopsy sampling area; B: Gross axial section of the pons and cerebellum showing 
the presence of a diffuse infiltrating tumor in the pons, reaching the middle cerebellar peduncles. The box indicates the sampling location 
of autopsy tissue at the non-necrotic tumor site; C-E: hematoxylin and eosin (H&E) staining of the vital tumor bulk showing morphologic 
heterogeneity compatible with WHO grade IV tumors (C and D) and grade I tumors (E); F-H: stains against intravascular plasma proteins 
pre-albumin (F), fibrinogen (G) and IgG (H) showing extravasation of these protein into the DIPG tumor parenchyma; I-K: hypoxia inducible 
factor-1α (HIF-1α) staining demonstrating a high expression of HIF-1α. (scale bar: 5 µm) 
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VUmc, study number: VUMC2009/237) and the Sci-
entific Committee of the Dutch Childhood Oncology 
Group (DCOG). In this study, brain tissue was ob-
tained within a post-mortem interval of less than six 
hours for Dutch patients and less than nine hours for 
patients from abroad, and was processed as forma-
lin-fixed paraffin-embedded tissue or snap frozen. 
Biopsy samples were MRI-guided and taken from 
the tumor area displaying the highest hyper-inten-
sity on T2-weighted image (Figure 1A). Autopsy sam-
ples were obtained from the non-necrotic tumor 
core in the pons (Figure 1B). 
Age-matched, healthy pontine tissue samples 
(n = 20) where obtained from the NIH NeuroBio-
Bank, Maryland, United States. Samples were se-
lected based on (i) brain region (pons), (ii) clinical 
brain diagnosis (unaffected control/sudden deaths), 
(iii) post-mortem interval (<17 hours), and (iv) pres-
ence of formalin-fixed tissue and frozen tissue. 
Table 1 shows patient and treatment charac-
teristics of the DIPG patients. Median age at diagno-
sis was 7.7 years (range 1.3-17.0 years). All patients 
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except for the youngest, received radiotherapy at di-
agnosis. Of these, at disease progression, three out 
of six received different chemotherapy regimens 
and two patients did not proceed to further treat-
ment. Median overall survival of patients that were 
autopsied was 19.5 months (range 5.5-24.0 
months). Supplementary Table 1 shows the charac-
teristics of the control group. Median age was 7.0 
years (range 1.0-19.0 years). All controls were 
healthy and had an accidental death. 
Immunohistochemistry 
Air-dried five-μm-thick cryosections were fixed 
in 2% formaldehyde for 10 min at room temperature 
(RT). Aldehyde groups were blocked in 0.1 g glycine 
in 100 ml distilled water for 10 min at RT. Sections 
were incubated overnight at RT with a primary anti-
body: (i) tight junction protein claudin-5 (1:50, Invi-
trogen, Carlsbad, CA, USA); (ii) tight junction protein 
ZO-1 (1:50, Invitrogen, Carlsbad, CA, USA); (iii) base-
ment membrane component laminin (1:500, Novus 
Biologicals, Abingdon UK); or (iv) pericyte marker 
PDGFR-β (1:500, Abcam, Cambridge, UK). The sec-
tions were co-stained with glial fibrillary acidic pro-
tein (GFAP; 1:1000, Merck, Darmstadt, Germany). 
The following day, the sections were incubated with 
Alexa Fluor®-labelled secondary antibodies, back-
ground was quenched with 0.1% Sudan black B, and 
sections were mounted in mounting medium (Vec-
tashield with 4',6-diamidino-2-fenylindool (DAPI); 
Vector Laboratories Inc., Burlingame, CA, USA). 
Five-μm-thick formalin-fixed paraffin-embed-
ded tissue sections were routinely stained with he-
matoxylin & eosin (H&E). A gross axial section 
through the pons and cerebellum was stained with 
Luxol fast blue-periodic acid-Schiff. For immuno-
histochemistry, sections were deparaffinized using 
xylene, and rehydrated through descending alcohol 
concentrations. Endogenous peroxidase activity was 
blocked by incubating the slides for 30 min in phos-
phate buffered saline (PBS) containing 0.3% H2O2. 
Heat-induced antigen retrieval was performed in 
0.01 M citrate buffer (pH 6.0). After washing in PBS, 
the slides were incubated overnight at RT with pri-
mary antibodies against P-gp (1:20; Millipore, CA, 
USA), BCRP (1:40; Abcam, Cambridge, UK), pre-albu-
min (1:50,000, Dako, Glostrup, Denmark), fibrinogen
 
 
Figure 2: Expression of tight junction proteins claudin-5 and zonula occludens-1 (ZO-1) in DIPG pre-treatment biopsy and post-mortem 
autopsy samples. In controls, claudin-5 and ZO-1 are sharply defined and have a segmented pattern (A and D). Claudin-5 and ZO-1 show 
reduced expression in DIPG samples (B, C, E, F). Please note the non-activated state of GFAP-expressing astrocytes in control tissue. (blue: 
nuclei; green: astrocytes; red: claudin-5 or ZO-1; scale bar: 5 µm)
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(1:1,600, Dako, Glostrup, Denmark), IgG (1:800, 
Dako, Glostrup, Denmark) and hypoxia-inducible 
factor 1α (HIF-1α; 1:40, Cayman Chemical, Michigan, 
USA). The next day, slides were incubated with 
ready-to-use EnVision™-HRP (Dako, Glostrup, Den-
mark) for 1 hour at RT and visualized with 3,3'Dia-
minobenzidine (DAB+ DAKO; 1:50, Glostrup, Den-
mark) for 10 min. The slides were counterstained 
with hematoxylin for 1 min and mounted with 
Quick-D mounting medium (Klinipath, Duiven, The 
Netherlands). 
Data analysis 
Sections were imaged using a Leica DM6000B 
microscope (400x magnification; Leica Microsys-
tems BV, Rijswijk, The Netherlands). From each tis-
sue slide, ten images were made. A semi-quantita-
tive analysis of the BBB staining, comparing DIPG 
samples with control samples, was done by two in-
dependent reviewers (FE and RH) using the Leica Ap-
plication Suite X: LAS X version 3.1.5.16308. The vas-
cular density was assessed on claudin-5-stained tis-
sue sections by counting the number of blood ves-
sels per mm2. The luminal diameter of the blood ves-
sels was measured with the Leica Application Suite 
X: LAS X version 3.1.5.16308. 
Statistics 
Data were analyzed using an independent sam-
ples t-test (p-value = 0.05) using IBM SPSS Statistics 
version 26. The Levene’s Test of Equality of Variance 
was used to first test the assumption of homogene-
ity or variance between the groups (p-value = 0.05). 
When equal variances were assumed, pooled esti-
mates were used for the independent t-test statis-
tics. When equal variances were not assumed, un-
pooled data and an adjustment to the degree of 




Figure 1 shows typical DIPG MRI features with 
enlargement of the pons and contrast enhance-
ment. Gross inspection confirms the presence of a 
partly necrotic and hemorrhagic tumor center in the 
pons. Microscopic examination shows variability of 
tumor cell morphology, ranging from grade I to 
grade IV according to the 2016 WHO classification of 
CNS tumors. Tumor areas were recognized based on 
cell density, the presence of (atypical) mitotic fig-
ures and features of high-grade glioma, including ne-
crosis and microvascular proliferation. In these tu-
mors, the integrity of the BBB is compromised, as 
demonstrated by extravasation of pre-albumin, fi-
brinogen and IgG. This corresponds with expression 
of HIF-1α, indicating tumor hypoxia. Notably, as ex-
pected for a heterogeneous tumor such as DIPG, the 
density of GFAP-expressing astrocytes varied 
throughout the tumor 20. Additionally, tumor cells 
were differentiated from pre-existing astrocytes by 
their higher expression levels of GFAP, conceivably 
also related to their less differentiated state 20. 
Immunohistochemical staining of claudin-5, 
ZO-1, laminin, PDGFR-β, P-gp and BCRP were evalu-
able in all samples. Expression of tight junction pro-
teins claudin-5 and ZO-1 was lower at inspection in 
all DIPG biopsy and autopsy samples compared to 
control samples (Figure 2). The expression of base-
ment membrane protein laminin was lower at the 
glial basement membrane in DIPG biopsy and au-
topsy samples. Interestingly, this was observed in 
both pre-existent vessels within the tumor cells and 
in neovascular proliferation (Figure 3). Expression of 
pericyte marker PDGFR-β was also reduced in both 
DIPG biopsy and autopsy samples (Figure 4). Efflux 
transporter P-gp expression was lower in DIPG bi-
opsy and autopsy samples, whereas the expression 
of BCRP was not different in DIPG compared to con-
trols (Figure 5). 
Vascular density 
Vascular density per mm2 was measured in 
non-necrotic biopsy and autopsy tissue. It was sig-
nificantly reduced in DIPG autopsy samples com-
pared to controls (1.5±1.2/mm2 versus 
17.5±9.5/mm2, respectively; t113,890 = 6.831, p-value 
<0.001; Figure 6A). Notably, the density of small 
blood vessels (<10 µm) was significantly lower in 
DIPG autopsy samples than in controls (t180,609 =  
-4.303, p-value <0.001), whereas the density of large 
blood vessels (≥10 µm) did not differ between 
groups (t597 = -0.835, p-value = 0.404). Most blood 
vessels in DIPG autopsy and control samples had a  
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diameter smaller than 10 µm. The median vascular 
diameter was 6.21 µm in DIPG autopsy samples 
(range 2.25-94.85 µm), versus 6.26 µm in controls 
(range 1.17-264.77 µm; Figure 6B). Due to the very 
small size of the biopsy samples, it was not possible 
to statistically analyze the vascular density and dia-
meter in these tissue samples. Visual inspection of 
three patients, however, showed a mean vascular 
density of 7.5 vessels per mm2, and a median vascu-




Figure 3: Expression of basement membrane component laminin in DIPG pre-treatment biopsy and post-mortem autopsy samples. In 
controls (A-C), laminin shows a continuous pattern. Laminin expression was reduced at the glial basement membrane in both DIPG biopsy 
(D-F) and autopsy samples (G-I). This was also observed in neovascularization in autopsy samples (J-L). Of note: neovascular proliferation 
was not detected in biopsy samples. (blue: nuclei; green: astrocytes; red: laminin; scale bar: 5 µm)
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Little research has been done to identify the 
NVU in DIPG, while it is hypothesized that treatment 
failure is caused by an intact BBB. As summarized by 
Figure 7, our study demonstrates structural changes 
in the NVU of DIPG patients that are already present 
at diagnosis, suggesting these to be tumor-related 
and not only due to treatment. 
All studied DIPG patients harbored a H3K27M 
mutation, thus fulfilling the diagnosis of DMG 
H3K27M according to the revised WHO classification 
8. Up to 85% of DIPG patients harbor this mutation 
21,22. Since three out of six DIPG autopsy patients 
were long-term survivors, the median overall sur-
vival of the patients in this group was longer than 
known from literature, 19.5 months versus 11 
months, respectively 7. Whether neuropathological 
grading (WHO II-IV), tumor location or the presence 
of a H3K27M mutation have an impact on survival is 
still not clear 22-24. 
The barrier properties of the NVU strongly de-
pend on the complex interaction between endothe-
lial cells and their tight junctions, pericytes, base-
ment membranes and astrocytes. In physiological 
conditions, tight junctions are formed by inter-endo-
thelial connections between transmembrane pro-
teins of the claudin-family  (claudin-1, 3, 5, and 12), 
which regulate the function of these tight junc-
tions25,26. Claudins are anchored into the endothelial 
cells by proteins from the zonula occludens-family 
(ZO-1, 2, and 3) that regulate adherens junctions and 
influence cytoskeletal organization, angioge- 
nic potential and cell migration 27. Moreover, ZO-1 is
 
 
Figure 4: Expression of pericyte marker PDGFR-β in DIPG pre-treatment biopsy and post-mortem autopsy samples. In controls (A-C), 
PDGFR-β shows a continuous pattern. Expression of PDGFR-β was reduced in both DIPG biopsy (D-F) and autopsy samples (G-I). (blue: 
nuclei; green: astrocytes; red: PDGFR-β; scale bar: 5 µm). 
Free Neuropathology 2:17 (2021) El-Khouly et al 





Figure 5: Expression of efflux transporters P-gp and BCRP in DIPG pre-treatment biopsy and post-mortem autopsy samples. P-gp and 
BCRP are sharply defined and have a segmented pattern in controls (A and D). Expression of P-gp was reduced in both DIPG samples (B 
and C). BCRP expression was unchanged in DIPG samples (E and F). (blue: nuclei; green: astrocytes; red: P-gp or BCRP; scale bar: 5 µm) 
 
responsible for the spatial organization of claudin-5 
by linking it to the actin cytoskeleton 25. Downregu-
lation of ZO-1 can lead to tight junction disruption 
and a larger intercellular distance between endothe-
lial cells and thus pathologically increased paracellu-
lar transport 27. Claudin-5 is most abundant in brain 
vessels (600-times higher expression than other 
claudins), where it has a heterogeneous distribution 
26. The highest claudin-5 expression is seen in capil-
laries and small post-capillary venules 25,28. In a clau-
din-5 knockout mouse model, an increased leakage 
of molecules up to 800 Da was observed 29, whereas 
the permeability of normal BBB only allows passage 
of molecules up to 500 Da 30,31. When additional 
tight junction proteins are downregulated, a size-de-
pendent increase in paracellular transport is seen of 
molecules with a size up to 10,000 Da 29,32. In our 
study, a reduced expression of claudin-5 and ZO-1 
was observed in DIPG patients both pre-treatment 
and post-mortem, indicating a barrier defect, and in-
creasing paracellular transport across the BBB 27. 
Nevertheless, there are more tight junction proteins 
of the zonula occludens and claudin-family ex-
pressed by brain endothelial cells. Whether possible 
downregulation of claudin-5 and ZO-1 is compen-
sated by overexpression of other tight junction pro-
teins remains unknown. 
Endothelial cells are surrounded by a basement 
membrane that contains laminin produced by peri-
cytes and astrocytes 33,34. Laminin is essential for 
basement membrane assembly and maintenance of 
NVU integrity 35. In our study, employing a pan- 
laminin antibody, we found that expression of lam-
inin was lower at the glial basement membrane in 
both DIPG biopsy and autopsy samples. This was ob-
served in pre-existent vessels amongst the tumor 
cells and in neovascular proliferation. Our results 
suggest a pathological involvement of pericytes and 
astrocytes in DIPG that could have consequences on 
the behavior of the endothelial cells, thus also dis-
rupting the integrity of the NVU 34. Immunohisto-
chemistry showed also a lower expression of PDGFR-
β in DIPG biopsy and autopsy samples, suggesting a 
reduction in pericytic coverage in DIPG NVU. Besides 
contributing to secretion of basement membrane 
components 33,34, pericytes are essential for regula-
ting capillary diameter and vessel stability 13. The 
possible reduction of pericytic coverage observed in 
our study may explain the possible downregulation 
of laminin at the glial basement membrane in DIPG 
patients.
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Figure 6: Vascular density and diameter in DIPG post-mortem autopsy and healthy control samples. A: vascular density in DIPG post-
mortem autopsy samples and healthy control samples. Mean vascular density was 1.5±1.2/mm2 in DIPG versus 17.5±9.5/mm2 in controls 
(red line). B: Vascular size distribution in DIPG post-mortem samples and healthy control samples. 
 
 
Figure 7: Graphical overview of the structural capillary changes observed in DIPG pre-treatment biopsy and post-mortem autopsy 
samples: lower expression of tight junction proteins claudin-5 and ZO-1, basement membrane component laminin, pericyte marker 
PDGFR-β and efflux transporter P-gp in DIPG biopsy and autopsy samples; unchanged expression of efflux transporter BCRP-1 in DIPG 
biopsy and autopsy samples. 
 
 
Under physiological conditions, P-gp and BCRP 
are the most dominantly expressed efflux transpor-
ters in de BBB 36,37. Our study shows a decreased P-
gp expression and unchanged BCRP expression in 
DIPG pre-treatment and post-mortem samples. This 
is in line with previous work showing a “moderate 
expression” of P-gp and intense staining of BCRP in 
DIPG tumor vasculature 10. 
Overall, our results show alterations of the 
NVU in DIPG patients, which could result in or reflect 
a more leaky NVU. This hypothesis of a leaky NVU is 
supported by the demonstrated extravasation of 
some intravascular proteins, such as pre-albumin, fi-
brinogen and IgG. Theoretically, this might positively 
influence influx of chemotherapeutic agents into the 
tumor, based on passive diffusion. Clinical data, 
however, do not support this possibility 38,39. A pos-
sible explanation for this discrepancy might be the 
markedly reduced vascular density in DIPG that 
could overrule the effects of a leaky NVU. Whether 
the reduction of vascular density is also present at 
diagnosis remains to be investigated. 
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Lack of therapy efficacy in DIPG has been linked 
to an intact BBB. Here, we demonstrated structural 
changes of the NVU together with a lower vascular 
density in these tumors. These findings have conse-
quences for drug administration, since coverage of 
the whole tumor, including the migrating/diffusely 
growing tumor cells, is essential. Our findings sug-
gest that drug administration techniques that 
mostly rely on vascular density for drug distribution, 
including conventional systemic administration and 
microbubble mediated focused ultrasound, might 
show limited efficacy in DIPG 12. In contrast, convec-
tion-enhanced delivery might be a more suitable 
technique, in which drug distribution across the tu-
mor relies on a positive pressure gradient instead of 
passive diffusion 12,40,41. Adding such a biological 
NVU perspective may help to better direct treat-
ment choices for DIPG patients in the future. 
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